Gregory Butler, MD
Ophthalmology · Washington, DCNPI 1376726091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 40.8% of the total. Reporting peaked in 2022 at $549 and has fallen 74.2% since, to $141 in 2025.
Across 69 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$777
- Bausch & Lomb Americas Inc.$354
- Alcon$173
- Glaukos Corporation$158
- Aerie Pharmaceuticals, Inc.$140
- Novartis$62
- plus $239 from 7 others
What the payments were for
- Food & beverage$1,904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $777 |
| Bausch & Lomb Americas Inc. | 9 | $354 |
| Alcon | 8 | $173 |
| Glaukos Corporation | 1 | $158 |
| Aerie Pharmaceuticals, Inc. | 7 | $140 |
| Novartis | 3 | $62 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $55 |
| Eyevance Pharmaceuticals LLC | 3 | $46 |
| Oyster Point Pharma, Inc. | 2 | $39 |
| Dompe US, Inc. | 1 | $35 |
| Kala Pharmaceuticals, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$246
- iAccess Precision Blade$158
- MIEBO$123
- LOTEMAX SM$106
How this compares
$1,904 in reported general payments places this provider in the 55th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimbrinzaBrinzolamide/Brimonidine Tart | 300 | $139,100 |
| RocklatanNetarsudil Mesylat/Latanoprost | 133 | $124,913 |
| RhopressaNetarsudil Mesylate | 91 | $74,740 |
| RestasisCyclosporine | 41 | $64,539 |
| VyzultaLatanoprostene Bunod | 42 | $31,038 |
| Azelastine Hcl | 433 | $26,172 |
| Latanoprost | 1,766 | $19,217 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 89 | $18,645 |
| Methazolamide | 39 | $15,285 |
| LumiganBimatoprost | 19 | $13,339 |
| Ketorolac Tromethamine | 153 | $10,111 |
| Brinzolamide | 41 | $9,449 |
| Cyclosporine | 17 | $8,483 |
| Prednisolone Acetate | 129 | $7,644 |
| Loteprednol Etabonate | 33 | $6,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $140 | $199,653224 claims |
| AlconSimbrinza | $173 | $139,100300 claims |
| AbbVieRestasis, Lumigan, Combigan | $777 | $82,94373 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $354 | $31,03842 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $55 | $6,95633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.